Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 14

NCT ID: NCT00593268 Active, not recruiting - Clinical trials for Subarachnoid Hemorrhage

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

Start date: June 2004
Phase:
Study type: Observational

In this project we are collecting cerebrospinal fluid and blood from patients at Vanderbilt Medical Center who have a subarachnoid hemorrhage which has followed the rupture of a brain aneurysm. We then propose to study the cerebrospinal fluid using a novel microscopic laser directed mass spectrometric analysis (MALDI) available at Vanderbilt. The cerebrospinal fluid and blood will then be analysed for different biological markers, protein expression and gene expression. These markers will then be statistically correlated with clinical data including prediction of vasospasm, time to vasospasm and response to standard therapy.

NCT ID: NCT00515281 Active, not recruiting - Clinical trials for Bronchopulmonary Dysplasia

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

NOVA2
Start date: May 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether inhaled nitric oxide improves the neurological outcome for premature infants.

NCT ID: NCT00123695 Active, not recruiting - Clinical trials for Subarachnoid Hemorrhage

Serial Echocardiography After Subarachnoid Hemorrhage

SEAS
Start date: May 2005
Phase: N/A
Study type: Observational

There is increasing interest in myocardial abnormalities following central nervous system events, such as subarachnoid hemorrhage (SAH). These cardiac abnormalities include ECG changes, decreased cardiac output, decreased blood pressure, specific cardiac enzyme elevations, and segmental wall motion abnormalities (SWMA). Interestingly, wall motion abnormalities and ECG changes have shown to be reversible, and therefore the dysfunction has been described as neurogenic myocardial stunning. The pathophysiology of cardiac dysfunction following SAH has not yet been fully elucidated. Many reports (mainly case reports) have been published, but so far no study has investigated the frequency of these abnormalities in a prospective manner, have correlated the occurrence of the different cardiac abnormalities, and have assessed which clinical variables can predict cardiac dysfunction. And only a limited number of studies have related neurological outcome with cardiac dysfunction.